Sign in Subscribe
Pharmaceutical industry

Chronic Kidney Disease Market to Register a CAGR of 6.6% by 2026

Strategic Insights

— 2 min read

The "Chronic Kidney Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report projects a significant growth in the Chronic Kidney Disease Market, with an expected Compound Annual Growth Rate (CAGR) of 6.6% during the forecast period. The market is driven by the increasing incidence of chronic kidney diseases, technological advancements in diagnostic tests, and the rising need for early detection. North America is expected to hold the largest market share, with the United States being a significant contributor due to its developed healthcare infrastructure and government initiatives offering lucrative reimbursement policies.

Key Takeaways:

  • The blood test segment for diagnosis is expected to witness high growth over the forecast period, with the demand increasing due to the high incidence of CKD worldwide.
  • The global prevalence of end-stage renal diseases (ESRD) is high and increasing at a significant rate, with around 850 million people worldwide suffering from kidney disorders.
  • In Singapore, the prevalence of CKD increased from approximately 12% to 17% from 2007 to 2017 and is expected to increase to approximately 24% by 2035.
  • North America held the largest market share in previous years and is expected to do the same in the forecast period, driven by developed healthcare infrastructure and government initiatives.
  • The lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%), and in women, it is about 1 in 82 (1.02%), indicating a big potential market demand for kidney disease diagnostics and therapeutics.
  • The market players are focusing on the launch of new products, with the U.S. Food and Drug Administration (FDA) approving Janssen Pharmaceutical's drug INVOKANA to reduce the risk of end-stage kidney disease and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease.

Statistics:

  • The Chronic Kidney Disease Market is expected to register a CAGR of 6.6% during the forecast period (2021-2026).
  • The blood test segment is expected to witness high growth over the forecast period due to the high incidence of CKD worldwide.
  • Around 850 million people worldwide suffer from kidney disorders, with the global prevalence of end-stage renal diseases (ESRD) increasing at a significant rate.
  • In Singapore, the prevalence of CKD increased from approximately 12% to 17% from 2007 to 2017 and is expected to increase to approximately 24% by 2035.
  • The lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%), and in women, it is about 1 in 82 (1.02%).
  • The U.S. Food and Drug Administration (FDA) approved Janssen Pharmaceutical's drug INVOKANA to reduce the risk of end-stage kidney disease and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease.

Sources:

  • "Chronic Kidney Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report from ResearchAndMarkets.com
  • World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), 2020
  • L. Y. Wong et al., "Prevalence of chronic kidney disease in Singapore: a systematic review and meta-analysis," International Journal of Nephrology, 2018.
  • American Cancer Society, "2020 Cancer Facts & Figures" report, 2020
  • U.S. Food and Drug Administration (FDA), press release, 2019 and 2020.

Read more